Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteVanillin (FEMA 3107), 4-hydroxy-3-methoxybenzaldehyde is a food additive.
More Information Supplier PageVanillin (FEMA 3107), 4-hydroxy-3-methoxybenzaldehyde is a food additive.
More Information Supplier PageVanillyl alcohol (4-Hydroxy-3-methoxybenzyl alcohol, Vanillin alcohol, Vanillic alcohol, 3-Methoxy-4-hydroxybenzyl alcohol), derived from vanillin, is used to flavor food.
More Information Supplier PageVanillyl Butyl Ether (4-(Butoxymethyl)-2-methoxyphenol), an ether of monohydroxybenzoic acid, is added to food products as a flavoring agent. It is also present in cosmetics and personal care products as a fragrance ingredient, oral care agent, hair conditioning agent, and warming or cooling agent.
More Information Supplier PageVanillylacetone (NSC 15335) is similar in chemical structure to other flavor chemicals such as vanillin and eugenol and is used as a flavor additive in spice oils and in perfumery to introduce spicy aromas. Vanillylacetone (Zingerone) alleviates oxidative stress and inflammation, down-regulates NF-κB mediated signaling pathways. Zingerone acts as an anti-mitotic agent, and inhibits the […]
More Information Supplier PageVanillylmandelic acid (VMA) is a chemical intermediate in the synthesis of artificial vanilla flavorings and is an end-stage metabolite of the catecholamines
More Information Supplier PageVanoxerine (GBR-12909) is a potent and selective inhibitor of the presynaptic dopamine uptake complex.
More Information Supplier PageVantictumab (Anti-FZD) is a monoclonal antibody targeting the Wnt signaling pathway with potential antineoplastic activity. Vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This results in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. MW: 145.5 […]
More Information Supplier PageVantictumab (Anti-FZD) is a monoclonal antibody targeting the Wnt signaling pathway with potential antineoplastic activity. Vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This results in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. MW: 145.5 […]
More Information Supplier PageVantictumab (Anti-FZD) is a monoclonal antibody targeting the Wnt signaling pathway with potential antineoplastic activity. Vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This results in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. MW: 145.5 […]
More Information Supplier PageVardenafil HCl Trihydrate (BAY38-9456) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
More Information Supplier PageVardenafil (BAY38-9456, Levitra, Staxyn) hydrochloride is a selective, orally active, potent inhibitor of phosphodiesterase (PDE) with IC50 of 0.7 nM, 11 nM and 180 nM for PDE5, PDE6 and PDE1, respectively.
More Information Supplier PageVarenicline(CP 526555) is highly selective and blocks more potently to α4β2 receptors than to other common nicotinic receptors (>500-fold α3β4, >3,500-fold α7, >20,000-fold α1βγδ), or to non-nicotinic receptors and transporters (>2,000-fold). Varenicline also acts as an agonist of 5-HT3 serotonine receptors.
More Information Supplier PageVarenicline(CP 526555) is highly selective and blocks more potently to α4β2 receptors than to other common nicotinic receptors (>500-fold α3β4, >3,500-fold α7, >20,000-fold α1βγδ), or to non-nicotinic receptors and transporters (>2,000-fold). Varenicline also acts as an agonist of 5-HT3 serotonine receptors.
More Information Supplier PageVarenicline (CP 526555, Chantix, Champix,CP 526555 dihydrochloride) dihydrochloride is a potent, partial agonist of α4β2 nicotinic acetylcholine receptor (nAChR) and α3β4 nAChR with EC50 of 2.3 μM and 55 μM, respectively. Varenicline dihydrochloride is a potent, full agonist of α7 nAChRs with EC50 of 18 μM. Varenicline is a prescription medication used for smoking cessation.
More Information Supplier PageVarenicline (CP 526555) Hydrochloride is a partial agonist of α4β2 nicotine acetylcholine receptor (nAChR) and α6β2 nicotine acetylcholine receptor (nAChR), with a Ki value of 0.12 nM and 0.14 nM for α6β2 nAChR and α4β2 nAChR, respectively, in the striatum of rats.
More Information Supplier PageVarenicline (CP 526555) Hydrochloride is a partial agonist of α4β2 nicotine acetylcholine receptor (nAChR) and α6β2 nicotine acetylcholine receptor (nAChR), with a Ki value of 0.12 nM and 0.14 nM for α6β2 nAChR and α4β2 nAChR, respectively, in the striatum of rats.
More Information Supplier PageVarenicline Tartrate (CP 526555-18, Chantix, Champix) is a nicotinic AChR partial agonist, used to treat nicotine addiction.
More Information Supplier PageVarespladib (LY315920) is a potent and selective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor with IC50 of 7 nM. Phase 3.
More Information Supplier PageVarespladib (LY315920) is a potent and selective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor with IC50 of 7 nM. Phase 3.
More Information Supplier PageVarespladib (LY315920) is a potent and selective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor with IC50 of 7 nM. Phase 3.
More Information Supplier PageVarisacumab (Anti-VEGFA) is a human recombinant monoclonal antibody targeting VEGFA. It may be used in research of Microvascular complications of diabetes 1 (MVCD1). MW :145.62 KD.
More Information Supplier PageVarisacumab (Anti-VEGFA) is a human recombinant monoclonal antibody targeting VEGFA. It may be used in research of Microvascular complications of diabetes 1 (MVCD1). MW :145.62 KD.
More Information Supplier PageVarisacumab (Anti-VEGFA) is a human recombinant monoclonal antibody targeting VEGFA. It may be used in research of Microvascular complications of diabetes 1 (MVCD1). MW :145.62 KD.
More Information Supplier PageVarlilumab (Anti-TNFRSF7 / CD27) is a human monoclonal antibody with activity against the CD27 receptor. It exhibits potential immunostimulating and antineoplastic activity. MW : 150 KD.
More Information Supplier PageVarlilumab (Anti-TNFRSF7 / CD27) is a human monoclonal antibody with activity against the CD27 receptor. It exhibits potential immunostimulating and antineoplastic activity. MW : 150 KD.
More Information Supplier PageVarlilumab (Anti-TNFRSF7 / CD27) is a human monoclonal antibody with activity against the CD27 receptor. It exhibits potential immunostimulating and antineoplastic activity. MW : 150 KD.
More Information Supplier PageVarlitinib (ARRY334543) is a selective and potent ErbB1(EGFR) and ErbB2(HER2) inhibitor with IC50 of 7 nM and 2 nM, respectively. Phase 2.
More Information Supplier PageVasicine, an alkaloid isolated from A. vasica, is a potential natural cholinesterase inhibitor, exhibits promising anticholinesterase activity in preclinical models and has been in development for treatment of Alzheimer’s disease.
More Information Supplier PageVasicine hydrochloride(Peganine hydrochloride) is a salt of vasicine (VAS), an alkaloid isolated from Adhatoda vasica, is a potential natural cholinesterase inhibitor. VAS inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).
More Information Supplier PageVasicine hydrochloride(Peganine hydrochloride) is a salt of vasicine (VAS), an alkaloid isolated from Adhatoda vasica, is a potential natural cholinesterase inhibitor. VAS inhibits both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).
More Information Supplier PageVatalanib 2HCl (PTK787, ZK 222584, cpg-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM in a cell-free assay, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4. Phase 3.
More Information Supplier PageVatalanib 2HCl (PTK787, ZK 222584, cpg-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM in a cell-free assay, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4. Phase 3.
More Information Supplier PageVatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1)) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). It can be used for the research of multiple sclerosis. MW: 144.56 KD.
More Information Supplier PageVatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1)) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). It can be used for the research of multiple sclerosis. MW: 144.56 KD.
More Information Supplier PageVatelizumab (Anti-Integrin a2b1 (ITGA2 & ITGB1)) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). It can be used for the research of multiple sclerosis. MW: 144.56 KD.
More Information Supplier PageVB124, a potent and selective MCT4 inhibitor, specifically inhibits lactate efflux/import in MDA-MB-231 cells expressing MCT4, and is used for the research of cardiac hypertrophy, heart failure, and metabolism.
More Information Supplier PageVB124, a potent and selective MCT4 inhibitor, specifically inhibits lactate efflux/import in MDA-MB-231 cells expressing MCT4, and is used for the research of cardiac hypertrophy, heart failure, and metabolism.
More Information Supplier PageVB124, a potent and selective MCT4 inhibitor, specifically inhibits lactate efflux/import in MDA-MB-231 cells expressing MCT4, and is used for the research of cardiac hypertrophy, heart failure, and metabolism.
More Information Supplier PageVB124, a potent and selective MCT4 inhibitor, specifically inhibits lactate efflux/import in MDA-MB-231 cells expressing MCT4, and is used for the research of cardiac hypertrophy, heart failure, and metabolism.
More Information Supplier PageVBIT-12 is a potent inhibitor of Voltage-dependent anion-selective channel 1 (VDAC1), directly interacting with purified VDAC1, reducing its channel conductance and preventing VDAC1 oligomerization.
More Information Supplier PageVBIT-12 is a potent inhibitor of Voltage-dependent anion-selective channel 1 (VDAC1), directly interacting with purified VDAC1, reducing its channel conductance and preventing VDAC1 oligomerization.
More Information Supplier PageVBIT-12 is a potent inhibitor of Voltage-dependent anion-selective channel 1 (VDAC1), directly interacting with purified VDAC1, reducing its channel conductance and preventing VDAC1 oligomerization.
More Information Supplier PageVBIT-12 is a potent inhibitor of Voltage-dependent anion-selective channel 1 (VDAC1), directly interacting with purified VDAC1, reducing its channel conductance and preventing VDAC1 oligomerization.
More Information Supplier PageVBIT-12 is a potent inhibitor of Voltage-dependent anion-selective channel 1 (VDAC1), directly interacting with purified VDAC1, reducing its channel conductance and preventing VDAC1 oligomerization.
More Information Supplier PageVBIT-4 is a voltage-dependent anion channel (VDAC) oligomerization inhibitor that decreases mitochondrial DNA (mtDNA) release, type I interferon (IFN) signaling, neutrophil extracellular traps, and disease severity in a mouse model of systemic lupus erythematosus.
More Information Supplier PageVBIT-4 is a voltage-dependent anion channel (VDAC) oligomerization inhibitor that decreases mitochondrial DNA (mtDNA) release, type I interferon (IFN) signaling, neutrophil extracellular traps, and disease severity in a mouse model of systemic lupus erythematosus.
More Information Supplier PageVBIT-4 is a voltage-dependent anion channel (VDAC) oligomerization inhibitor that decreases mitochondrial DNA (mtDNA) release, type I interferon (IFN) signaling, neutrophil extracellular traps, and disease severity in a mouse model of systemic lupus erythematosus.
More Information Supplier Page
